NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Syneos Health, Inc. (NASDAQ: SYNH) Class Period: May 10, 2017 to February 27, 2019 Lead Plaintiff Deadline: April 30, 2019
During the class period, Syneos Health, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Syneos Health’s internal control over financial reporting was inadequate; (2) concerns regarding Syneos Health’s internal control over financial reporting would result in heightened regulatory scrutiny and an SEC investigation into the company’s revenue accounting policies, internal controls and related matters; and (3) as a result, defendants’ statements about Syneos Health’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the SYNH lawsuit: http://www.kleinstocklaw.com/pslra-1/syneos-h...orm?wire=3
Healthcare Services Group, Inc. (NASDAQ: HCSG) Class Period: April 11, 2017 to March 4, 2019 Lead Plaintiff Deadline: May 21, 2019
The lawsuit alleges that Healthcare Services Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) Defendant Wahl either knew or was reckless in not knowing that the Company had been accused of strategically rounding quarterly earnings per share, and therefore investors could not rely upon the Company's track record without conducting a thorough investigation into the allegations; (b) Defendants concealed that the SEC had written to the Company in November 2017 to inquire into the Company's earnings per share rounding practices; and (c) the Company concealed that the SEC delivered a subpoena to the Company in March 2018 demanding the Company produce documents in connection with how it calculated earnings per share.
Get additional information about the HCSG lawsuit: http://www.kleinstocklaw.com/pslra-1/healthca...orm?wire=3
U.S. Xpress Enterprises, Inc. (NYSE: USX) Class Period: Purchasers of common stock pursuant/and or traceable to the initial public offering completed in June 2018 Lead Plaintiff Deadline: May 10, 2019
The complaint alleges that the Offering Documents failed to disclose that: (1) a shortage of trucks was negatively impacting U.S. Xpress’s dedicated division; (2) (a) certain shipping patterns had been performing differently than expected and, as a result, (b) utilization, driver retention and hiring were being negatively affected, and as a result, (c) U.S. Xpress’s dedicated accounts, including one large account, were being negatively impacted; and as a result, (d) U.S. Xpress’s OTR division was providing continued support to the dedicated division; (3) (a) U.S. Xpress failed to stay informed regarding two large liability events; and as a result (b) U.S. Xpress’s insurance claim expense was understated; and (4) U.S. Xpress’s cost per mile for driver wages and independent contractors was exceeding the Company’s internal expectations.
Get additional information about the USX lawsuit: http://www.kleinstocklaw.com/pslra-1/u-s-xpre...orm?wire=3
American Renal Associates Holdings, Inc. (NYSE: ARA) Class Period: August 10, 2016 to March 27, 2019 Lead Plaintiff Deadline: May 28, 2019
According to the complaint, American Renal Associates Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal’s accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission (“SEC”) investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times.
Get additional information about the ARA lawsuit: http://www.kleinstocklaw.com/pslra-1/american...orm?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
